|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2008
|
|
gptkbp:ATCCode
|
N02AX06
|
|
gptkbp:brand
|
gptkb:tapentadol
|
|
gptkbp:contraindication
|
paralytic ileus
acute or severe bronchial asthma
severe respiratory depression
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
extended-release tablet
immediate-release tablet
|
|
gptkbp:genericName
|
gptkb:tapentadol
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nucynta
|
|
gptkbp:indication
|
chronic pain
moderate to severe acute pain
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:MAO_inhibitors
serotonergic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
addiction
respiratory depression
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
somnolence
|
|
gptkbp:usedFor
|
pain management
|
|
gptkbp:bfsParent
|
gptkb:Tapentadol
gptkb:Depomed,_Inc.
|
|
gptkbp:bfsLayer
|
7
|